The concern that cumulative radiation exposure over a lifetime of healthcare-related imaging could boost the risk of cancer is addressed in the latest launch from GE Healthcare. It's rolled out DoseWatch Explore to track practice-level radiation dose data from its computed tomography (CT) systems.
Abbott and GE Healthcare are teaming up for a diagnostics collaboration aimed at improving treatment for patients with atrial fibrillation, planning to combine the companies' innovative technology to speed up diagnosis for individuals with heart rhythm disorders.
Major Western device and medical technology firms launched Asia Pacific Medical Technology Association, or APACMed, pledging the association would unite a fragmented effort to work with regulators across a region that is both lucrative and frustrating on issues ranging from import rules to public tender guidelines.
GE is divesting most of its GE Capital financial services arm to focus on its core strengths in industrial equipment, like airplane engines and MRIs and other imaging devices.
GE Healthcare announced that its diagnostic laboratory company, Clarient, will soon deploy Omnyx's proprietary software, as pathology pivots away from visual diagnosis and toward quantitative computer-based tools.
As the med tech industry turns its attention to devices that can treat and prevent bedsores, a team of GE researchers is developing an innovative handheld probe that can prevent the sores, or pressure ulcers, from forming during hospital stays.
GE Healthcare is co-developing a novel ultrasound device to diagnose the effectiveness of chemotherapy in breast cancer patients developed by a hospital affiliated with the University of Toronto.
GE told FierceMedicalDevices in an email that the recall was voluntarily initiated following a single safety incident in India, where some users had disabled the so-called magnetic rundown unit, because the company "wanted to ensure that the human error was not occurring at other sites globally."
GE touted the strength of its healthcare business in the U.S., saying the country compensates for slowing growth in countries like Japan and Russia and is a headwind against unfavorable exchange rates abroad.
Israeli medical device company InSightec closed a $59 million Series D round led by major institutional investors in the U.S. and Asia. It's left room for existing shareholders to invest an additional $3.5 million through the end of January.